xanthenes has been researched along with Parkinsonian Disorders in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
Calon, F; Di Paolo, T; Grégoire, L; Hornykiewicz, O; Rajput, A; Rajput, AH; Samadi, P | 1 |
Mitsumoto, Y; Mori, A; Nakai, M; Watanabe, A | 1 |
3 other study(ies) available for xanthenes and Parkinsonian Disorders
Article | Year |
---|---|
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes | 2013 |
Metabotropic glutamate receptor II in the brains of Parkinsonian patients.
Topics: Aged; Aged, 80 and over; Amino Acids; Antiparkinson Agents; Brain; Cocaine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Parkinsonian Disorders; Postmortem Changes; Radioligand Assay; Receptors, Metabotropic Glutamate; Tritium; Xanthenes | 2009 |
1-methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (Deltapsi(m)) in rat striatum.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benzimidazoles; Carbocyanines; Coloring Agents; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Fluorometry; Male; Membrane Glycoproteins; Membrane Potentials; Membrane Transport Proteins; Mitochondria; Nerve Tissue Proteins; Oxazines; Oxidation-Reduction; Parkinsonian Disorders; Piperazines; Presynaptic Terminals; Rats; Rats, Wistar; Sodium Cyanide; Synaptosomes; Tyrosine 3-Monooxygenase; Xanthenes | 2003 |